Risk factor
Very high price volatility
Profitability factor
Favourable price performance
About
Infant Bacterial Therapeutics AB (publ) is a biopharmaceutical company in the clinical development phase, specializing in creating treatments for serious and uncommon conditions that impact prematurely born infants. Based in Stockholm, Sweden, and established in 2013, the company's primary therapeutic candidate is IBP-9414, which aims to both prevent necrotizing enterocolitis (NEC) – a severe intestinal disease – and enhance digestive tolerance in these vulnerable newborns. Additionally, they are progressing IBP-1016, designed to address gastroschisis, a critical congenital defect affecting infants.
Company Valuation
Based on key historical and expected multiples, the stock is fairly valued relative to its peers. Specifically, the stock is undervalued on EV/EBITDA.